Mannkind Corporation (MNKD) Dividend History

Company News

• More Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza®)

  A Phase 4 study found that more adults with type 1 diabetes achieved target A1C levels when switching from multiple daily injections or insulin pumps to inhaled insulin (Afrezza). The data showed continued improvement in glycemic control for those who remained on Afrezza or switched to it.

  GlobeNewswire Inc.
• "Rule Breaker Investing" Market Cap Game Show: Bill Mann vs. Bill Barker

  Our first-ever twin bill.

  The Motley Fool

  Featured Companies: AAPL AMZN CAVA CHWY GLP IT MAN MANH MCD QCOM QRVO SNBR TGT TGTX VZ WOOF ZM
• INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions

  INHALE-3 STUDY REVEALS POSITIVE READOUT IN HEAD-TO-HEAD COMPARISON OF INHALED INSULIN VS. USUAL CARE IN T1D; NEW DATA PRESENTED

  GlobeNewswire Inc.
• Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions

  INHALE-3 STUDY RESULTS TO BE PRESENTED DURING A 90-MINUTE SYMPOSIUM ON SATURDAY, JUNE 22 AT THE AMERICAN DIABETES ASSOCIATION’S 84TH SCIENTIFIC SESSIONS

  GlobeNewswire Inc.
• MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix

  MANNKIND TO ESTABLISH BOSTON-AREA RESEARCH & DEVELOPMENT FOOTHOLD AND EXPAND PORTFOLIO OF DRY POWDER INHALATION TECHNOLOGY IN TRANSACTION WITH PULMATRIX

  GlobeNewswire Inc.